Перегляд за Автор "Gusachenko, I."

Зараз показуємо 1 - 5 з 5
  • Ескіз недоступний
    Документ
    Efficacy profile daily injection filgrastim in chemotherapy-induced (ct) febrile neutropenia (fn) in patients with acute leukemia (al): ukranian retrospective study in a real-life cohort
    (Clinical Limphoma, Myeloma & Leukemia, 2024-09-01) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Гусаченко, Юлія володимирівна
    Materials and methods: 59 primary patients with AL (median age: 53.8, range: 9.23 years; male 35 (59.3%), female 24 (40.7%); ECOG I-II) were included in the study during 2021-2023 and received the standard induction CT according to ESMO Clinical Practice Guidelines in our department. The patients were enrolled into two groups: 31(52.5%) and 28(47.5%) pts in control and study to Filgrastim groups, respectively. 21(35.6%) acute myeloid leukemia (AML) pts and 10(17%) acute lymphoblastic leukemia (ALL) pts were involved in IA and IIA control groups; 17(28.8%) AML-pts and 11(18.6%) ALL-pts were contained in IB and IIB study groups, respectively. Results. We verified Gr 4 neutropenia in 17(80.95%) pts of group IA and 14 (82.35%) pts of group IB which received regimen 7+3 with/without etoposide. Duration time of Gr 4 neutropenia in group IB versus group IA was 1.5 times less, t(38)= 3.65, р˂0.001. FN developed significantly rarer in IB group with G-CSFs, X2(1, N=38) = 4.87, p˂0.03. Among the patients with ALL was registered Gr 4 neutropenia in 6 (60%) pts of group IIA and 6 (54.5%) pts of group IIB. Duration time of FN was 2.7 times less in IIB group with G-CSFs than in group IIA, t(21)= 6.62, р˂0.00001. But there was no difference in the number of FN episodes developed in IIB vs IIA groups, p˃0.05. Conclusions. Filgrastim effectively prevents the development of FN in patients with AML against the background of severe cytostatic neutropenia. Thus, the use of Filgrastim made it possible to reduce the duration of severe neutropenia in patients with AL during induction CT.
  • Ескіз недоступний
    Документ
    L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
    (ООО «МОРИОН», 2017-12) Skrypnyk, I.; Maslova, G.; Lymanets, T.; Gusachenko, I.; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Лиманець, Тетяна Володимирівна
  • Ескіз недоступний
    Документ
    Quality of life evaluation in acute leukemia patients receiving induction chemotherapy
    (European society for medical oncology, 2018-10) Lymanets, T. V.; Skrypnyk, I. M.; Maslova, G. S.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна
    Background: Over the past decades, special attention has been paid to study of quality of life (QoL) indicators in hematological patients receiving chemotherapy (CT). Nowadays QoL is conceptually viewed as an important complement to traditional objective evaluation measures. Aim. To assess QoL in patients with acute leukemia (AL) depending on the presence of concomitant ischemic heart disease (1HD) during the induction CT. Methods: Our study involved 83 patients with newly diagnosed AL, of which 19 were lymphoblastic, 64-myeloid leukemia, aged 16-72,43 (51.8%) men, 40 (48.2%) women, according to ECOG l-II. Patients received standard induction CT. According to concomitant IFID patients were divided into groups: I (n — 47) - AL without cardio­ logical diseases; II (n = 36) - AL with concomitant IHD. Patients were evaluated using SF-36 questionnaire to calculate physical and mental health components before treatment and after 2 induction courses of CT reaching remission.
  • Ескіз недоступний
    Документ
    Quality of life in acute leukemia patients with comorbid ischemic heart disease
    (2018-06-14) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна Сергіївна
  • Ескіз недоступний
    Документ
    Risk assessment of anthracycline cardiotoxicity in patients with acute leukemia and concomitant ischemic heart disease
    (Hemasphere journal, 2019) Lymanets, T. V.; Skrypnyk, I. M.; Maslova, H. S.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна
    Background: Great attention has recently been focused on the problem of chemotherapy (CT) complications in patients with acute leukemia (AL). Notable among them is the anthracycline cardiotoxicity (AC), the development of which greatly inhibits the carrying out of CT in full doses, which significantly reduces the patients’ chances for life. The presence of concomitant ischemic heart disease (IHD) potentiates the formation of AC, increases the risk of myocardial injury development. Aims: To assess the risk factors of AC development on low cumulative doses of anthracycline antibiotics (AA) and to increase the efficacy of AC prevention in patients with AI, taking into account concomitant IHD. Methods: The study involved 147 patients with newly diagnosed AL, 72 (49%) males and 75 (51%) females, mean age 54.7 ± 9.3 years, ECOG I-II. All patients were treated in hematology department of Poltava Regional Clinical Hospital n.a.M.V.Sklifosovsky. Depending on the IHD presence, the patients were divided into two groups: I (n = 81)-AL pts without concomitant cardiovascular diseases; II (n = 66)-AL pts with IHD. Due to ongoing AC prevention with L-arginine patients of both groups were further subdivided: IA (n = 47) and IIA (n = 36)—pts receiving CT; IB (n = 34) and IIB (n = 30)-pts, who received CT with prophylaxis of AC with L-arginine. The study was approved by the local ethical committee and all patients and all patients signed the inform consent before they were included. The examination was carried out twice: at baseline and after induction CT, when remission was achieved and AA low cumulative doses <200 mg/m2 were reached. The cardiotoxic effect of AA was evaluated by echocardiography and ITolter ECG monitoring and considered to be according to CTCAE 4.03 as reduction of left ventricular ejection fraction (l.VF.F) more than 10% of baseline and QTc prolongation exceeded 450ms. The episodes of “silent ischemia” were assessed on the basis of ST segment depression by 1 mm or more in the absence of typical pain syndrome.